Ovid Therapeutics Inc.
Company Stats
- Market Cap
- $486.3M
- as of Sep 30, 2026
- Shares Outstanding
- 195.3M
- Free Float
- 84.6%
Income Statement
- Revenue
- $7.3M
- Operating Income
- -$42.4M
- Net Income
- -$17.4M
- EBITDA
- -$42.2M
- Revenue Growth, 3Y
- 69.0%
- FCF Margin, 3Y Avg
- -7372.1%
- FCF Margin, Worst Year
- -11689.0%
Cash Flow
- Free Cash Flow
- -$38.3M
- FCF Yield
- -7.9%
- Owner FCF Yield
- -8.9%
Balance Sheet
- Cash & Equivalents
- $13.2M
Returns & Capital
- SBC, 3Y Avg
- $6.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $7.3M | -$38.3M | -528.6% |
| FY2024 | $566,000 | -$56.0M | -9898.8% |
| FY2023 | $392,000 | -$45.8M | -11689.0% |
| FY2022 | $1.5M | -$56.5M | -3756.6% |
| FY2021 | $208.4M | $118.4M | 56.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges